Open-Label Randomized Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination With Pembrolizumab in HLA-A2+ Subjects With NY-ESO-1 and/or LAGE 1A Positive Relapsed and Refractory Multiple Myeloma (rrMM) (ADP-0011-008) (KEYNOTE-487)

Trial Profile

Open-Label Randomized Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination With Pembrolizumab in HLA-A2+ Subjects With NY-ESO-1 and/or LAGE 1A Positive Relapsed and Refractory Multiple Myeloma (rrMM) (ADP-0011-008) (KEYNOTE-487)

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs NY-ESO-1c259 TCR-transduced lymphocytes (Primary) ; Pembrolizumab (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Adaptimmune
  • Most Recent Events

    • 03 Nov 2017 According to an Adaptimmune media release, the study design of this trial will be presented at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
    • 25 May 2017 Status changed from planning to recruiting, according to an Adaptimmune media release.
    • 15 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top